High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice

Journal of Virological Methods

Volumn 143, Issue 2, 2007, Pages 125-131

  Zhang, Zhi Shan ^a,b   Yan, Yan Sheng ^a   Weng, Yu Wei ^a   Huang, Hai Long ^a   Li, Shi Qing ^a   He, Shi ^a   Zhang, Jian Ming ^a  

^a Fujian Center for Disease Control and Prevention   (China)

^b Quanzhou First Hospital   (China)

Author keywords

Dengue vaccine; Dengue virus; Envelope domain III; HPLC

Indexed keywords

CARRIER PROTEIN; DENGUE VACCINE; NEUTRALIZING ANTIBODY; UREA; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; CELL INCLUSION; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DENGUE VIRUS 2; DRUG PURIFICATION; ESCHERICHIA COLI; EXPRESSION VECTOR; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNIZATION; IMMUNOGENICITY; INOCULATION; ION EXCHANGE CHROMATOGRAPHY; LETHAL DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; RECOMBINANT PLASMID; SOLUBILIZATION; VIRUS PLAQUE; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, ION EXCHANGE; CLONING, MOLECULAR; CYTOPATHOGENIC EFFECT, VIRAL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PLAQUE ASSAY; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

DENGUE VIRUS; DENGUE VIRUS TYPE 2; ESCHERICHIA COLI; MUS;

EID: 34250724435     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2007.02.012     Document Type: Article

References (29)

1. Agarwal R., Kapoor S., Nagar R., Misra A., Tandon R., Mathur A., Misra A.K., Srivastava K.L., and Chaturvedi U.C. A clinical study of the patients with dengue hemorrhagic fever during the epidemic of 1996 at Lucknow India. Southeast Asian J. Trop. Med. Public Health 30 (1999) 735-740
2. Bhamarapravati N., and Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 18 (2000) 44-47
3. Bisht H., Chugh D.A., Swaminathan S., and Khanna N. Expression and purification of dengue virus type 2 envelop as a fusion with Hepatitis B surface antigen in Pichia pastoris. Protein Exp. Purif. 23 (2001) 84-96
4. Chen Y., Maguire T., and Marks R.M. Demonstration of binding of dengue envelope protein to target cells. J. Virol. 70 (1996) 8765-8772
5. Chiu M.W., and Yang Y.L. Blocking the dengue virus 2 infections on BHK-21 cells with purified recombinant dengue virus 2 E protein expressed in Escherichia coli. Biochem. Biophys. Res. Commun. 309 (2003) 672-678
6. Eckles K.H., Dubios D.R., and Putnak R. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. Am. J. Trop. Med. Hyp. 69 (2003) 12-16
7. Feighny R., Burrous J., McCown J., Hoke C., and Putnak R. Purification of native dengue-2 viral proteins and ability of purified proteins to protect mice. Am. J. Trop. Med. Hyg. 47 (1992) 405-412
8. Fonseaca K., Khoshnood K., Shope R.E., and Mason P.W. Flavivirus type-specific produced from fusion of the E protein gene with the E. coli trpE gene. Am. J. Trop. Med. 44 (1991) 500-508
9. Gubler D.J., and Clark G.G. Dengue/dengue haemorragic fever: the emergence of a global health problem. Emerg. Infect. Dis. 1 (1995) 55-57
10. Guirakhoo F., Arroyol J., Pugachev K.V., Miller C., Zhang Z.-X., Weltzin R., Georgakopoulos K., Catalan J., Ocran S., Soike K., Ratterree M., and Monath T.P. Construction, safety, and immunogenecity in non human primates of a chimeric yellow fever dengue virus tetravalent vaccine. J. Virol. 75 (2001) 7290-7304
11. Guirakhoo F., Pugachev K., and Zhang Z. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 78 (2004) 4761-4775
12. Hermida L., Rodriguez R., Lazo L., Silva R., Zulueta A., Chinea G., Lopez C., Guzman M.G., and Guillen G. A dengue-2 envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J. Virol. Methods 115 (2004) 41-49
13. Jaiswal S., Khanna N., and Swaminathan S. High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli. Protein Exp. Purif. 33 (2003) 80-91
14. Kelly E.P., Greene J.J., and King A.D. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 18 (2000) 2549-2559
15. Megret F., Hugnot J.P., and Falconar M.K. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue envelope glycoprotein. Virology 187 (1992) 480-491
16. Men R., Wyatt L., and Tokimatsu I. Immunization of rhesus monkeys with a recombinant of modified vaccina virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 18 (2000) 3113-3122
17. Mota J., Acosta M., and Argotte R. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 23 (2005) 3469-3476
18. Putnak R., Barvir D.A., and Burrous J.M. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J. Infect. Dis. 174 (1996) 1176-1184
19. Rosen L. Comments on the epidemiology, pathogenesis and control of dengue. Med. Trop. 59 (1999) 495-498
20. Simmons M., Nelson W.M., Wu S.J., and Hayes C.G. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am. J. Trop. Med. Hyg. 58 (1998) 655-662
21. Simmons M., Murphy G.S., and Kochel T. Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. Am. J. Trop. Med. Hyp. 65 (2001) 420-426
22. Simmons M., Murphy G.S., and Hayes C.G. Short report: antibody response of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am. J. Trop. Med. Hyg. 65 (2001) 159-161
23. Srivastava A.K., Putnak J.R., Warren R.L., and Hoke Jr. C.H. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 11 (1995) 1251-1258
24. Staropoli I., Clement J.M., Frenkiel M.P., Hofnung M., and Deubel V. Dengue virus envelope glycoprotein can be secreted from insect cells as a fusion with maltose-binding protein. J. Virol. Methods 56 (1996) 179-189
25. Staropoli I., Frenkiel M.-P., Megret F., and Deubel V. Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice. Vaccine 15 (1997) 1946-1954
26. Sugrue R.J., Cui T., and Xu J. The production of recombinant dengue virus E protein using Escherichia coli and Pichia pastoris. J. Virol. Methods 69 (1997) 159-169
27. van der Most R.G., Murali-Krishna K., Ahmed R., and Strauss J.H. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J. Virol. 74 (2000) 8094-8101
28. Wei H.Y., Jiang L.F., and Xue Y.H. Secreted expression of dengue virus type 2 full-length glycoprotein in Pichia pastoris. J. Virol. Methods 109 (2003) 17-23
29. Wu S.F., Liao C.L., and Lin Y.L. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine 21 (2003) 3919-3929